5/23
08:47 am
virx
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $13.00 to $11.00. They now have an "outperform" rating on the stock.
Medium
Report
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $13.00 to $11.00. They now have an "outperform" rating on the stock.
5/17
04:23 pm
virx
Viracta Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]
Neutral
Report
Viracta Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]
5/17
04:05 pm
virx
Viracta Therapeutics Announces New Employment Inducement Grants
Neutral
Report
Viracta Therapeutics Announces New Employment Inducement Grants
5/14
07:08 am
virx
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer [Yahoo! Finance]
Medium
Report
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer [Yahoo! Finance]
5/14
07:00 am
virx
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
Medium
Report
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
5/9
04:24 pm
virx
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/9
04:05 pm
virx
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
5/7
04:05 pm
virx
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
Low
Report
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
4/17
03:26 pm
virx
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $13.00 price target on the stock.
Medium
Report
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $13.00 price target on the stock.
4/16
10:55 am
virx
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Medium
Report
Viracta Therapeutics, Inc. (NASDAQ: VIRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
4/15
08:13 am
virx
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma [Yahoo! Finance]
High
Report
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma [Yahoo! Finance]
4/15
08:00 am
virx
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
High
Report
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
4/1
08:39 am
virx
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan [Yahoo! Finance]
Medium
Report
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan [Yahoo! Finance]
4/1
08:30 am
virx
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
Medium
Report
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
3/8
09:31 am
virx
Thinking about buying stock in Quantum-Si, Victoria's Secret, Viracta Therapeutics, CERo Therapeutics, or Weyerhaeuser?
Medium
Report
Thinking about buying stock in Quantum-Si, Victoria's Secret, Viracta Therapeutics, CERo Therapeutics, or Weyerhaeuser?
3/7
04:05 pm
virx
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Medium
Report
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update